Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population

References

• Centers for Disease Control and Prevention. New hepatitis C infections nearly tripled over five years. Published 2017 May 11 [accessed 2021 Sept 7]. https://www.cdc.gov/nchhstp/newsroom/2017/Hepatitis-Surveillance-Press-Release.html.
   Google Scholar
• Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, Holtzman D. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108:175–81.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Hepatitis C - annual epidemiological report for 2015. Published 2017 Dec 6. [accessed 2021 May 28]. https://www.ecdc.europa.eu/en/publications-data/hepatitis-c-annual-epidemiological-report-2015.
   Google Scholar
• Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Global Health. 2017;5:e1192–e207.
   PubMed Web of Science ®Google Scholar
• Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS. 2011;6:501–07.
   PubMed Web of Science ®Google Scholar
• Zepatier (elbasvir and grazoprevir) tablets, for oral use [package insert]. Whitehouse Station, NJ, USA: Merck Sharp & Dohme Corp.; 2019.
   Google Scholar
• Zepatier (elbasvir and grazoprevir) tablets, for oral use [summary of product characteristics]. Hoddesdon, Hertfordshire, UK: MSD Ltd.; 2018.
   Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen B-Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gane E, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152:164–75.e4.
   PubMed Web of Science ®Google Scholar
• Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H, Martin P, Pol S, Londoño M-C, Hassanein T, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–45.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319–27.
   PubMed Web of Science ®Google Scholar
• Hezode C, Colombo M, Bourliere M, Spengler U, Ben-Ari Z, Strasser SI, Lee WM, Morgan L, Qiu J, Hwang P, et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology. 2017;66:736–45.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Lawitz E, Kwo PY, Hézode C, Peng C-Y, Howe AYM, Hwang P, Wahl J, Robertson M, Barr E, et al. Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology. 2017;152:1372–82 e2.
   PubMed Web of Science ®Google Scholar
• Asselah T, Reesink H, Gerstoft J, Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante‐Appiah E, Wahl J, Nguyen B-Y, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int. 2018;38:1583–91.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng C-Y, Conway B, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Internal Med. 2016;165:625–34.
   PubMed Web of Science ®Google Scholar
• Wong ES, Wang V, Liu CF, Hebert PL, Maciejewski ML. Do Veterans Health Administration enrollees generalize to other populations? Med Care Res Rev. 2016;73:493–507.
   PubMed Web of Science ®Google Scholar
• US Department of Veterans Affairs. Veterans Health Administration. About VHA. Updated 2021 Apr 23 [accessed 2021 Sept 7]. https://www.va.gov/health/aboutvha.asp.
   Google Scholar
• National Kidney Foundation. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1–163.
   Web of Science ®Google Scholar
• Kramer JR, Puenpatom A, Erickson KF, Cao Y, Smith D, El-Serag HB, Kanwal F. Real-world effectiveness of elbasvir/grazoprevir in HCV-infected patients in the US Veterans Affairs Healthcare system. J Viral Hepat. 2018;25:1270–79.
   Google Scholar
• Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2017;65:426–38.
   PubMed Web of Science ®Google Scholar
• Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Internal Med. 2015;163:215–23.
   PubMed Web of Science ®Google Scholar
• Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, Cunningham CO, Johnson N, Laraque F, Litwin AH. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196–201.
   PubMed Web of Science ®Google Scholar
• Macias J, Morano LE, Tellez F, Granados R, Rivero-Juárez A, Palacios R, Ríos M, Merino D, Pérez-Pérez M, Collado A, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. J Hepatol. 2019;71:45–51.
   PubMed Web of Science ®Google Scholar
• Christensen S, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H, Zimmermann T, Weber B, Reimer J, Serfert Y, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? Addiction. 2018;113:868–82.
   PubMed Web of Science ®Google Scholar
• Stecker T, Han X, Curran GM, Booth BM. Characteristics of women seeking intensive outpatient substance use treatment in the VA. J Womens Health (Larchmt). 2007;16:1478–84.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Hagan H. Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend. 2012;124:95–107.
   PubMed Web of Science ®Google Scholar
• Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, et al. Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection. Clin Infect Dis. 2020;70:123–31.
   PubMed Web of Science ®Google Scholar
• Rojas Rojas T, Di Beo V, Delorme J, Barre T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, et al. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: the ANRS FANTASIO project. Int J Drug Policy. 2019;72:61–68.
   PubMed Web of Science ®Google Scholar
• Valerio H, Alavi M, Law M, Tillakeratne S, Amin J, Janjua NZ, Krajden M, George J, Matthews GV, Hajarizadeh B, et al. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. J Hepatol. 2021;74:293–302.
   PubMed Web of Science ®Google Scholar